Proinflammatory cytokines in Parkinson’s disease and current treatment approaches

Ahmet Berk

doi:10.30574/gscarr.2020.2.1.0012

Authors

Ahmet Berk Elazığ Fethi Sekin City Hospital 23050-Elazığ, Turkey.

DOI:

https://doi.org/10.30574/gscarr.2020.2.1.0012

Keywords:

Current approaches, Neurodegenerative disease, Neuroinflammation, Parkinson's disease, Proinflammatory cytokines

Abstract

Parkinson's disease is a neurodegenerative disease characterized by progressive degeneration of dopaminergic neurons in the substantia nigra region. As the etiology is not clear, treatment in this disease is rather symptomatic and inadequate to prevent the progression of the disease. However, recent studies have demonstrated the strong association of neuroinflammation and proinflammatory cytokines with disease pathology. In this review, the relationship of proinflammatory cytokines with the pathology of Parkinson's disease is discussed and current treatment approaches targeting these mechanisms are evaluated.

Metrics

Metrics Loading ...

References

Twelves D, Perkins KS and Counsell C. (2003). Systematic review of incidence studies of Parkinson's disease. Mov Disord, 18(1), 19-31.

Rocha NP, de Miranda AS and Teixeira AL. (2015). Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies. Biomed Res Int, 628192.

Gao HM, Liu B, Zhang W and Hong JS. (2003). Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci, 24(8), 395-401.

Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, et al. (2006). Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res, 6(5), 261-281.

Knott C, Wilkin GP and Stern G. (1999). Astrocytes and microglia in the substantia nigra and caudate-putamen in Parkinson's disease. Parkinsonism Relat Disord, 5(3), 115-122.

Alrafiah A, Al-Ofi E, Obaid MT and Alsomali N. (2019). Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients. Biomed Res Int, 2690205.

Barnum CJ and Tansey MG. (2012). Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease? Curr Neurol Neurosci Rep, 12(4), 350-358.

Jankovic J. (2008). Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 79(4), 368-376.

Ren Y, Li H, Xie W, Wei N and Liu M. (2019). MicroRNA195 triggers neuroinflammation in Parkinson's disease in a Rhoassociated kinase 1dependent manner. Mol Med Rep, 19(6), 5153-5161.

Mao H and Ding L. (2019). Downregulation of miR-21 suppresses 1-methyl-4-phenylpyridinium-induced neuronal damage in MES23.5 cells. Exp Ther Med, 18(4), 2467-2474.

Lin QS, Chen P, Wang WX, Lin CC, Zhou Y, Yu LH, et al. (2019). RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease. Lab Invest.

Nissen SK, Shrivastava K, Schulte C, Otzen DE, Goldeck D, Berg D, et al. (2019). Alterations in Blood Monocyte Functions in Parkinson's Disease. Mov Disord.

Gasparotto J, Ribeiro CT, Bortolin RC, Somensi N, Rabelo TK, Kunzler A, et al. (2017). Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation. Sci Rep, 7(1), 8795.

Guan J, Yang B, Fan Y and Zhang J. (2017). GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease. Neuroimmunomodulation, 24(1), 60-66.

Gao Y, Tang H, Nie K, Zhu R, Gao L, Feng S, et al. (2019). Hippocampal damage and white matter lesions contribute to cognitive impairment in MPTP-lesioned mice with chronic cerebral hypoperfusion. Behav Brain Res, 368, 111885.

Javed H, Azimullah S, Haque ME and Ojha SK. (2016). Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease. Front Neurosci, 10, 321.

Jung YY, Katila N, Neupane S, Shadfar S, Ojha U, Bhurtel S, et al. (2017). Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32beta transgenic mice. Neurochem Int, 102, 79-88.

Brombacher TM, Nono JK, De Gouveia KS, Makena N, Darby M, Womersley J, et al. (2017). IL-13-Mediated Regulation of Learning and Memory. J Immunol, 198(7), 2681-2688.

Lee PC, Raaschou-Nielsen O, Lill CM, Bertram L, Sinsheimer JS, Hansen J, et al. (2016). Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. Environ Res, 151, 713-720.

Ryan M, Eatmon CV and Slevin JT. (2019). Drug treatment strategies for depression in Parkinson disease. Expert Opin Pharmacother, 20(11), 1351-1363.

Acuna L, Hamadat S, Corbalan NS, Gonzalez-Lizarraga F, Dos-Santos-Pereira M, Rocca J, et al. (2019). Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by alpha-Synuclein Fibrillary Aggregates. Cells, 8(8).

Kandil EA, Sayed RH, Ahmed LA, Abd El Fattah MA and El-Sayeh BM. (2019). Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease. Clin Exp Pharmacol Physiol.

Li Y, Zeng Y, Meng T, Gao X, Huang B, He D, et al. (2019). Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-kappaB signaling pathways. Int Immunopharmacol, 75, 105739.

Poirier AA, Cote M, Bourque M, Morissette M, Di Paolo T and Soulet D. (2016). Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease. Neurobiol Aging, 48, 61-71.

Zhang G, Yang G and Liu J. (2019). Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson's disease in mice. Life Sci, 232, 116600.

Ardah MT, Merghani MM and Haque ME. (2019). Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates alpha-synuclein aggregation in vitro. Neurochem Int, 128, 115-126.

Javed H, Azimullah S, Meeran MFN, Ansari SA and Ojha S. (2019). Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson's Disease. Int J Mol Sci, 20(7).

Javed H, Azimullah S, Abul Khair SB, Ojha S and Haque ME. (2016). Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone. BMC Neurosci, 17(1), 58.

Singh S, Mishra A, Srivastava N, Shukla R and Shukla S. (2018). Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. Mol Neurobiol, 55(1), 583-602.

Zhang X, Yang Y, Du L, Zhang W and Du G. (2017). Baicalein exerts anti-neuroinflammatory effects to protect against rotenone-induced brain injury in rats. Int Immunopharmacol, 50, 38-47.

Sharma N and Nehru B. (2018). Curcumin affords neuroprotection and inhibits alpha-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model. Inflammopharmacology, 26(2), 349-360.

Magistrelli L, Amoruso A, Mogna L, Graziano T, Cantello R, Pane M, et al. (2019). Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Front Immunol, 10, 969.

Tamtaji OR, Naderi Taheri M, Notghi F, Alipoor R, Bouzari R and Asemi Z. (2019). The effects of acupuncture and electroacupuncture on Parkinson's disease: Current status and future perspectives for molecular mechanisms. J Cell Biochem, 120(8), 12156-12166.